Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial

Clinical trial on hypertension and cholesterol management

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a large-scale clinical trial designed to determine the best treatment strategies for preventing heart attacks and other cardiovascular events in patients with hypertension and dyslipidemia. The study was sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and was conducted between 1994 and 2002.

Background

Hypertension and high cholesterol are major risk factors for cardiovascular disease, which is the leading cause of death worldwide. The ALLHAT trial aimed to compare the effectiveness of different classes of antihypertensive and lipid-lowering medications in reducing the incidence of myocardial infarction and other cardiovascular outcomes.

Study Design

The ALLHAT trial was a randomized, double-blind, multicenter study that enrolled over 42,000 participants aged 55 and older with hypertension and at least one additional risk factor for coronary heart disease. Participants were randomly assigned to receive one of the following antihypertensive treatments:

• A diuretic (chlorthalidone)
• A calcium channel blocker (amlodipine)
• An angiotensin-converting enzyme inhibitor (lisinopril)

In addition, a subset of participants with elevated cholesterol levels was also randomized to receive either a statin (pravastatin) or usual care.

Results

Hypertension is a major risk factor for cardiovascular disease

The results of the ALLHAT trial were published in several major medical journals. The study found that the diuretic chlorthalidone was as effective as, or more effective than, the other antihypertensive agents in preventing major cardiovascular events. The trial also demonstrated that the statin pravastatin did not significantly reduce the incidence of coronary heart disease compared to usual care in the subset of participants with moderately elevated cholesterol levels.

Implications

The findings of the ALLHAT trial had significant implications for clinical practice. The results supported the use of diuretics as a first-line treatment for hypertension, particularly in older adults. The trial also raised questions about the effectiveness of statins in certain populations, leading to further research and discussion in the medical community.

Criticism and Controversy

The ALLHAT trial faced some criticism regarding its design and interpretation of results. Some experts argued that the choice of comparator drugs and the specific populations studied may have influenced the outcomes. Despite these criticisms, the trial remains a landmark study in the field of cardiovascular medicine.

Related pages

• Hypertension
• Cholesterol
• Cardiovascular disease
• Clinical trial